Rezolute Aktie - RZLT

Professionelle Tools für Privatanleger.

Premium

Current Price

5,0993

Gebot

4,90

Fragen

5,12

Volumen

366.895

4,5601 Tagesbereich 5,10

0,9199 52-Wochen-Bereich 6,1856

Marktkapitalisierung

295,469M

Handelsende

4,60

Handelsbeginn

4,58

Letzte Trade

500

5.0993

(formt)

Letzter Handelszeitpunkt

Finanzvolumen

US$ 1.804.220

VWAP

4,9175

Durchschnittliches Volumen (3 Mio.)

384.491

Ausgegebene Aktien

57.943.066

Dividendenrendite

Kurs-Gewinn-Verhältnis

-4,29

Gewinn pro Aktie (EPS)

-1,18

Erlöse

Nettogewinn

-68,46M

Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to si... Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402. Mehr anzeigen

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.rezolutebio.com

Hauptsitz

Las Vegas, Nevada, USA

Gegründet

Rezolute Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RZLT. The last closing price for Rezolute was US$4,60. Over the last year, Rezolute shares have traded in a share price range of US$ 0,9199 to US$ 6,1856.

Rezolute currently has 57.943.066 shares in issue. The market capitalisation of Rezolute is US$266,54 million. Rezolute has a price to earnings ratio (PE ratio) of -4.29.

Form 8-K - Current report

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative...

FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.1893	3.85539714868	4.91	5.0993	4.4	557205	4.66620992	CS
4	0.2293	4.70841889117	4.87	5.52	4.4	417332	4.90523238	CS
12	-0.4107	-7.45372050817	5.51	6.1856	4.07	384491	5.00229749	CS
26	0.4393	9.42703862661	4.66	6.1856	3.98	366123	4.95296381	CS
52	3.9293	335.837606838	1.17	6.1856	0.9199	432811	3.92416413	CS
156	1.1993	30.7512820513	3.9	6.1856	0.72	195768	3.55692143	CS
260	-15.0407	-74.680734856	20.14	21.2	0.72	150021	3.93509911	CS

RZLT - Frequently Asked Questions (FAQ)

What is the current Rezolute share price?

The current share price of Rezolute is US$ 5,0993

How many Rezolute shares are in issue?

Rezolute has 57.943.066 shares in issue

What is the market cap of Rezolute?

The market capitalisation of Rezolute is USD 266,54M

What is the 1 year trading range for Rezolute share price?

Rezolute has traded in the range of US$ 0,9199 to US$ 6,1856 during the past year

What is the PE ratio of Rezolute?

The price to earnings ratio of Rezolute is -4,29

What is the reporting currency for Rezolute?

Rezolute reports financial results in USD

What is the latest annual profit for Rezolute?

The latest annual profit of Rezolute is USD -68,46M

What is the registered address of Rezolute?

The registered address for Rezolute is 187 E WARM SPRINGS ROAD, SUITE B, LAS VEGAS, NEVADA, 89119

What is the Rezolute website address?

The website address for Rezolute is www.rezolutebio.com

Which industry sector does Rezolute operate in?

Rezolute operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
DGNXDiginex Ltd	US$ 49,18 (228,09%)	3,34M
SLXNSilexion Therapeutics Corporation	US$ 3,1301 (131,86%)	330,45M
KRKR36Kr Holdings Inc	US$ 9,10 (114,12%)	23,61M
SPGCSacks Parente Golf Inc	US$ 0,6001 (57,92%)	52,17M
XFORX4 Pharmaceuticals Inc	US$ 0,7542 (56,54%)	42,5M
ZKINZK International Group Co Ltd	US$ 0,4813 (-41,21%)	3,1M
MGOLMGO Global Inc	US$ 0,1019 (-38,73%)	70,52M
BACKIMAC Holdings Inc	US$ 0,7869 (-35,50%)	2,37M
EYENEyenovia Inc	US$ 0,03695 (-35,18%)	25,31M
HAOHaoxi Health Technology Ltd	US$ 2,52 (-31,89%)	484,94k
NVDANVIDIA Corporation	US$ 123,70 (-4,10%)	466,94M
SLXNSilexion Therapeutics Corporation	US$ 3,1301 (131,86%)	330,45M
OCEAOcean Biomedical Inc	US$ 0,249929 (-24,26%)	186,52M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0,428 (-6,98%)	148,12M
RIMEAlgorhythm Holdings Inc	US$ 0,0259 (-16,18%)	138,96M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Rezolute Inc (RZLT)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Rezolute Inc

RZLT Neueste Nachrichten

Form 8-K - Current report

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

RZLT - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Rezolute Inc (RZLT) Börsenkurse

Rezolute Inc (RZLT)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Rezolute Inc

RZLT Neueste Nachrichten

RZLT - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen